112 related articles for article (PubMed ID: 22984902)
21. Fluorescent ligands to investigate GPCR binding properties and oligomerization.
Cottet M; Faklaris O; Falco A; Trinquet E; Pin JP; Mouillac B; Durroux T
Biochem Soc Trans; 2013 Feb; 41(1):148-53. PubMed ID: 23356275
[TBL] [Abstract][Full Text] [Related]
22. Past, present and future of vasopressin and oxytocin receptor oligomers, prototypical GPCR models to study dimerization processes.
Cottet M; Albizu L; Perkovska S; Jean-Alphonse F; Rahmeh R; Orcel H; Méjean C; Granier S; Mendre C; Mouillac B; Durroux T
Curr Opin Pharmacol; 2010 Feb; 10(1):59-66. PubMed ID: 19896898
[TBL] [Abstract][Full Text] [Related]
23. Preparation of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene)acetamide derivatives as novel arginine vasopressin V(2) receptor agonists.
Tsukamoto I; Koshio H; Akamatsu S; Kuramochi T; Saitoh C; Yatsu T; Yanai-Inamura H; Kitada C; Yamamoto E; Sakamoto S; Tsukamoto S
Bioorg Med Chem; 2008 Nov; 16(21):9524-35. PubMed ID: 18835174
[TBL] [Abstract][Full Text] [Related]
24. Pharmacological characterization of RWJ-676070, a dual vasopressin V(1A)/V(2) receptor antagonist.
Gunnet JW; Wines P; Xiang M; Rybczynski P; Andrade-Gordon P; de Garavilla L; Parry TJ; Cheung WM; Minor L; Demarest KT; Maryanoff BE; Damiano BP
Eur J Pharmacol; 2008 Aug; 590(1-3):333-42. PubMed ID: 18599033
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and structure-activity relationships of amide derivatives of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene)acetic acid as selective arginine vasopressin V2 receptor agonists.
Tsukamoto I; Koshio H; Kuramochi T; Saitoh C; Yanai-Inamura H; Kitada-Nozawa C; Yamamoto E; Yatsu T; Shimada Y; Sakamoto S; Tsukamoto S
Bioorg Med Chem; 2009 Apr; 17(8):3130-41. PubMed ID: 19321349
[TBL] [Abstract][Full Text] [Related]
26. Fluorescent pseudo-peptide linear vasopressin antagonists: design, synthesis, and applications.
Durroux T; Peter M; Turcatti G; Chollet A; Balestre MN; Barberis C; Seyer R
J Med Chem; 1999 Apr; 42(7):1312-9. PubMed ID: 10197974
[TBL] [Abstract][Full Text] [Related]
27. Tetrahydroquinoline sulfonamides as vasopressin 1b receptor antagonists.
Scott JD; Miller MW; Li SW; Lin SI; Vaccaro HA; Hong L; Mullins DE; Guzzi M; Weinstein J; Hodgson RA; Varty GB; Stamford AW; Chan TY; McKittrick BA; Greenlee WJ; Priestley T; Parker EM
Bioorg Med Chem Lett; 2009 Nov; 19(21):6018-22. PubMed ID: 19800231
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and evaluation of nonpeptide substituted spirobenzazepines as potent vasopressin antagonists.
Xiang MA; Chen RH; Demarest KT; Gunnet J; Look R; Hageman W; Murray WV; Combs DW; Rybczynski PJ; Patel M
Bioorg Med Chem Lett; 2004 Jun; 14(12):3143-6. PubMed ID: 15149662
[TBL] [Abstract][Full Text] [Related]
29. Mapping the binding site of six nonpeptide antagonists to the human V2-renal vasopressin receptor.
Macion-Dazard R; Callahan N; Xu Z; Wu N; Thibonnier M; Shoham M
J Pharmacol Exp Ther; 2006 Feb; 316(2):564-71. PubMed ID: 16234409
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and evaluation of spirobenzazepines as potent vasopressin receptor antagonists.
Xiang MA; Chen RH; Demarest KT; Gunnet J; Look R; Hageman W; Murray WV; Combs DW; Patel M
Bioorg Med Chem Lett; 2004 Jun; 14(11):2987-9. PubMed ID: 15125974
[TBL] [Abstract][Full Text] [Related]
31. Small-molecule vasopressin-2 receptor antagonist identified by a g-protein coupled receptor "pathway" screen.
Yangthara B; Mills A; Chatsudthipong V; Tradtrantip L; Verkman AS
Mol Pharmacol; 2007 Jul; 72(1):86-94. PubMed ID: 17435162
[TBL] [Abstract][Full Text] [Related]
32. Affinity and efficacy of selective agonists and antagonists for vasopressin and oxytocin receptors: an "easy guide" to receptor pharmacology.
Chini B; Manning M; Guillon G
Prog Brain Res; 2008; 170():513-7. PubMed ID: 18655904
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and characterization of the first fluorescent nonpeptide NPY Y1 receptor antagonist.
Schneider E; Keller M; Brennauer A; Hoefelschweiger BK; Gross D; Wolfbeis OS; Bernhardt G; Buschauer A
Chembiochem; 2007 Nov; 8(16):1981-8. PubMed ID: 17876753
[TBL] [Abstract][Full Text] [Related]
34. Distribution of vasopressin and oxytocin binding sites in the brain and upper spinal cord of the common marmoset.
Schorscher-Petcu A; Dupré A; Tribollet E
Neurosci Lett; 2009 Sep; 461(3):217-22. PubMed ID: 19539696
[TBL] [Abstract][Full Text] [Related]
35. Distinct receptor subtypes mediate arginine vasopressin-dependent ACTH release and intracellular calcium mobilization in rat pituitary cells.
Perdonà E; Arban R; Griffante C
Eur J Pharmacol; 2012 Mar; 679(1-3):16-23. PubMed ID: 22285855
[TBL] [Abstract][Full Text] [Related]
36. Design and synthesis of the first selective agonists for the rat vasopressin V(1b) receptor: based on modifications of deamino-[Cys1]arginine vasopressin at positions 4 and 8.
Pena A; Murat B; Trueba M; Ventura MA; Wo NC; Szeto HH; Cheng LL; Stoev S; Guillon G; Manning M
J Med Chem; 2007 Feb; 50(4):835-47. PubMed ID: 17300166
[TBL] [Abstract][Full Text] [Related]
37. Fluorescent agonists and antagonists for vasopressin/oxytocin G protein-coupled receptors: usefulness in ligand screening assays and receptor studies.
Mouillac B; Manning M; Durroux T
Mini Rev Med Chem; 2008 Sep; 8(10):996-1005. PubMed ID: 18782052
[TBL] [Abstract][Full Text] [Related]
38. Atropisomerism in the vaptan class of vasopressin receptor ligands: the active conformation recognized by the receptor.
Tabata H; Nakagomi J; Morizono D; Oshitari T; Takahashi H; Natsugari H
Angew Chem Int Ed Engl; 2011 Mar; 50(13):3075-9. PubMed ID: 21404400
[No Abstract] [Full Text] [Related]
39. Subtlety of the structure-affinity and structure-efficacy relationships around a nonpeptide oxytocin receptor agonist.
Frantz MC; Rodrigo J; Boudier L; Durroux T; Mouillac B; Hibert M
J Med Chem; 2010 Feb; 53(4):1546-62. PubMed ID: 20104850
[TBL] [Abstract][Full Text] [Related]
40. A Gly/Ala switch contributes to high affinity binding of benzoxazinone-based non-peptide oxytocin receptor antagonists.
Hawtin SR; Ha SN; Pettibone DJ; Wheatley M
FEBS Lett; 2005 Jan; 579(2):349-56. PubMed ID: 15642343
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
